查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
電子臨床結果評估解決方案的全球市場：2023-2030
市場調查報告書
商品編碼
1279675

電子臨床結果評估解決方案的全球市場：2023-2030

Global Electronic Clinical Outcome Assessment Solutions Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

電子臨床結果評估解決方案的全球市場預計到 2022 年將達到 12.39 億美元，到 2030 年將達到 42.498 億美元，並實現利潤豐厚的增長。 預計在預測期內（2023-2030 年）複合年增長率將達到 17.3%。

電子臨床結果評估解決方案是醫生快速有效地進行隨機臨床研究的工具。 這些 eCOA 系統從多個位置持續收集數據，以幫助改善患者安全和招募流程。 隨著早期試驗獲得更多優先權，最終用戶使用這些系統的頻率更高。

電子臨床結果評估解決方案市場包括許可的、基於雲的和網絡託管的產品，增加了這些產品的市場份額。 患者報告評估、臨床醫生報告評估、觀察者報告評估和績效評估等方法的市場份額正在增長，因為它們屬於電子臨床結果評估解決方案的範圍。

市場動態

主要製藥和生物製藥公司越來越多地將臨床試驗研究外包，這推動了電子臨床結果評估解決方案市場的增長。

慢性病患病率上升、新治療方式的開發、新產品的發布以及電子平台等技術改進正在促進全球電子臨床結果評估解決方案市場的增長。

為了更好地了解治療效果，監管機構強調了對患者健康狀況進行更廣泛研究的重要性。 因此，越來越多地使用臨床結果評估 (COA) 來評估各種慢性疾病的治療效果。 在某些情況下，它還有助於新藥的批准。

此外，市場將隨著許多新服務的引入而擴大。 例如，2021 年 6 月，Signant Health 宣布了一項新的加速計劃，在不影響所提供臨床數據質量的情況下，將研究準備時間縮短 50% 以上，從而導致市場擴張顯著增加。

不斷增加的研發支出和技術進步為製造商創造了有利可圖的機會

電子臨床結果評估解決方案在許多臨床試驗中越來越被廣泛接受，因此存在巨大的市場機會。 對電子臨床結果評估解決方案中使用的方法和產品的高需求將為製造商提供有利可圖的增長選擇。

隨著主要參與者大力投資於研發能力以改進其尖端技術，新興市場有機會。 許多公司正在開發尖端技術來治療多種疾病，並通過臨床試驗評估最佳治療方法。

高昂的引進成本阻礙了市場增長

中型製藥公司和臨床試驗發起人越來越擔心構建 eCOA 解決方案的初始成本高。 電子數據收集可能需要大量的初始成本（例如，購買軟件平板電腦或計算機、設備成本、與軟件開發商簽訂合同、手機上網等）。

COVID-19 影響分析

除了 COVID 之前、COVID 和 COVID 之後的情景外，COVID-19 的分析還包括價格動態（與 COVID 情景相比，大流行期間的價格變化）、供需範圍（交易限制、封鎖）。 ，由於後續問題引起的供需變化），政府舉措（政府機構的市場，行業和部門振興努力），以及製造商的戰略舉措。

俄烏衝突影響分析

由於該地區的主要市場參與者數量較少，估計俄羅斯-烏克蘭衝突對全球電子臨床結果評估解決方案市場的影響較小。 然而，原材料進出口的影響預計在預測期內對全球電子臨床結果評估解決方案市場的增長影響不大。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按投放方式分類的摘要
  • 方法片段
  • 最終用戶的片段
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 主要製藥公司和生物製藥公司增加了臨床試驗研究的外包
      • 對基於雲的服務的需求不斷增長
    • 約束因素
      • 引進成本高
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法律法規分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按交付方式

  • 網絡託管
  • 基於雲
  • 許可行業

第 8 章方法

  • 患者報告的評估
  • 臨床醫生報告的評估
  • 觀察員報告的評估
  • 績效/評估

第 9 章最終用戶

  • 製藥和生物製藥公司
  • 門診中心
  • 簽約研發組織
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 中東和非洲
    • 各地區的主要動態

第11章競爭格局

  • 競爭場景
  • 市場定位/份額分析
  • 併購分析

第12章公司簡介

  • 艾昆緯控股公司
    • 公司簡介
    • 交付模式組合和說明
    • 財務摘要
    • 主要發展狀況
  • Oracle Corporation
  • Dassault Systems SE
  • Parexel International Corporation
  • IBM Corporation
  • Signant Health
  • Clario
  • eClinical Solutions LLC
  • Castor
  • Anju Software

第13章 附錄

簡介目錄
Product Code: HCIT4784

Market Overview

The global electronic clinical outcome assessment solutions market reached US$ 1,239.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,249.8 million by 2030. The market is expected to exhibit a CAGR of 17.3% during the forecast period (2023-2030).

Clinical Outcome Assessment (eCOA) Solutions are tools that let doctors conduct randomized clinical studies quickly and effectively. These eCOA systems help collect data consistently from numerous locations to improve the safety of patients and the hiring process. End users utilize these systems more often because early-phase testing is being prioritized more.

The electronic clinical outcome assessment solutions market includes licensed, cloud-based, and web-hosted delivery methods, which has increased the market share for these products. The approaches such as patient-reported outcome, clinician-reported outcome, observer-reported outcome, and performance outcome fall under the purview of electronic clinical outcome assessment solutions, which has increased its market share.

Market Dynamics

Increasing Externalization of Clinical Trial Studies by Large Pharmaceutical And Biopharmaceutical Companies Drives the Growth of the Electronic Clinical Outcome Assessment Solutions Market.

The prevalence of chronic illnesses is increasing, new treatment methods are being developed, new products are being released, and technology improvements such as electronic platforms are all contributing to the growth of the global electronic clinical outcome assessment solutions market.

In order to more accurately characterize therapeutic gain, regulatory agencies have stressed the significance of examining broader elements of patient well-being. Clinical outcome assessments (COAs) are therefore being used more frequently to evaluate the effectiveness of treatments for different chronic conditions. In certain instances, they have even contributed to the approval of new drugs.

The market will also expand as a result of the introduction of numerous new services. For instance, in June 2021, Signant Health unveiled a new acceleration program that reduces study setup time by 50 percent or more without compromising the caliber of clinical data delivered, leading to significant market expansion.

Growing R&D Expenditure and Technological Advancements Creates Lucrative Opportunities for Manufacturers.

There is a sizable market opportunity for electronic clinical outcome assessment solutions as it is becoming more widely acceptable in numerous clinical trials. Manufacturers are going to have profitable choices for growth as demand for approaches and products utilized for electronic clinical outcome assessment solutions will be high.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Numerous businesses are creating cutting-edge technologies to treat several conditions, and evaluate the best treatment options via clinical trials.

The High Cost of Implementation Will Hamper the Market Growth.

Concern over the initial high cost of creating an eCOA solution is growing among mid-sized pharmaceutical producers and clinical trial sponsors. Electronic data collection may need a substantial initial financial outlay (for instance, to purchase tablets or computers with software, incur equipment costs, engage software developers, or use cellular internet).

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterward issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global electronic clinical outcome assessment solutions market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global electronic clinical outcome assessment solutions market growth over the forecast period.

Segment Analysis

The global electronic clinical outcome assessment solutions market is segmented based on delivery mode, approach, end-user, and region.

Patient Reported Outcome From Approach Segment Accounts for 46.7% of Electronic Clinical Outcome Assessment Solutions Market Share Owing to Rising Technological Advancements.

The health state of a patient is evaluated using patient-reported outcome measures (PROMs) at a certain period. The PROMs tools can be used to treat a problem while it is being treated or while the patient is unwell. The effectiveness of an intervention can occasionally be assessed using pre- and post-event PROMs.

In order to receive high-quality clinical care, patients must be able to describe their symptoms, feelings, and any side effects from any prescribed medications. The pharmaceutical business understood how critical it was to take patient-reported outcomes (PROs) and biomarkers of health improvement into account.

When medical service research started emphasizing enhancing patients' quality of life while undergoing optimal medical therapy, the distinction between medical results and treatment outcomes became more distinct. Consequently, the demand for identifiable, reliable, and valid patient-reported measures (PROMs) increased.

Geographical Analysis

North America Accounted for Approximately 33.9% of the Market Share Owing to the Strong Presence of Major Players and Increasing Research and Development.

Manufacturers have chances to expand their operations in this region because of the rising demand for electronic clinical outcome assessment solutions for various disorders in North America. This region has many producers and suppliers, and its rapid economic development has raised industrial production of electronic clinical outcome assessment solutions products, which has increased the demand.

The marketplace for electronic clinical outcome assessment solutions is anticipated to grow quickly as a result of an increase in clinical trials across the continent. As demand for medicinal research increases, clinical trials are expanding more and more in the US and Canada. Clinicians around the area rely on cutting-edge technologies for data management. Clinicians advise using eCOA options for clinical trial planning because to the necessity of their accessibility.

Competitive Landscape

The major global players in the electronic clinical outcome assessment solutions market include: IQVIA Holdings Inc, Dassault Systems SE, Oracle Corporation, Parexel International Corporation, Signant Health, IBM Corporation, Clario, Castor, eClinical Solutions LLC and Anju Software among others.

Why Purchase the Report?

  • To visualize the global electronic clinical outcome assessment solutions market segmentation based on delivery mode, approach, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of electronic clinical outcome assessment solutions market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global electronic clinical outcome assessment solutions market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Delivery Mode
  • 3.2. Snippet by Approach
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 4.1.1.2. Growing demand for cloud based services
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of implementation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Delivery Mode

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 7.1.2. Market Attractiveness Index, By Delivery Mode
  • 7.2. Web Hosted *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cloud-Based
  • 7.4. Licensed Industries

8. By Approach

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Patient-reported outcome *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinician-reported outcome
  • 8.4. Observer-reported outcome
  • 8.5. Performance outcome

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Pharmaceutical & Biopharmaceutical Companies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Care Center
  • 9.4. Contract Research Organizations
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. IQVIA Holdings Inc *
    • 12.1.1. Company Overview
    • 12.1.2. Delivery Mode Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Oracle Corporation
  • 12.3. Dassault Systems SE
  • 12.4. Parexel International Corporation
  • 12.5. IBM Corporation
  • 12.6. Signant Health
  • 12.7. Clario
  • 12.8. eClinical Solutions LLC
  • 12.9. Castor
  • 12.10. Anju Software

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us